GlassScriptPhysician profile
Arturo J Otero
NPI 1437253044
$14,826.91
in general payments reported to CMS, 2019-2025
73 companies · $2,990 in 2025
The $2,990 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,517 · 2020: $1,352 · 2021: $1,725 · 2022: $2,117 · 2023: $2,044 · 2024: $3,083 · 2025: $2,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,116.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,960.15 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,274.25 | 2019-2025 | |
| Biogen, INC. | $1,062.23 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Pfizer INC. | $1,035.14 | 2019-2025 | |
| Csl Behring | $995.49 | 2020-2025 | Hizentra |
| Ucb, INC. | $616.76 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Amgen INC. | $516.25 | 2019-2025 | Uplizna |
| Neurocrine Biosciences, INC. | $382.66 | 2019-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $381.42 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Argenx US, INC. | $322.58 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Lilly USA, LLC | $316.90 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Neurelis, INC. | $295.84 | 2020-2025 | Valtoco |
| Eisai INC. | $293.49 | 2019-2025 | |
| Allergan, INC. | $291.77 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $284.63 | 2019-2021 |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arturo Otero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.